Performance evaluation of a rapid multiplex point-of-care microfluidic immunofluorescence assay for the detection of SARS-CoV-2 Antigen and Flu A/B

In this application note, the performance of the LumiraDx SARS-CoV-2 & Flu A/B Test was evaluated versus RT-PCR using anterior nasal swabs from symptomatic patients. The LumiraDx SARS-CoV-2 & Flu A/B Test is an automated, rapid, microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.